A randomized, open-label, standard controlled, parallel group study of efficacy and safety of baclofen, and chlordiazepoxide in uncomplicated alcohol withdrawal syndrome

A randomized, open-label, standard controlled, parallel group study of efficacy and safety of baclofen, and chlordiazepoxide in uncomplicated alcohol withdrawal syndrome

Background: Alcohol withdrawal syndrome (AWS) is a distressing condition, generally controlled by benzodiazepines (BZD's). Baclofen, a gamma-aminobutyric acid-B (GABAB) agonist, has also shown promising results in controlling AWS. As there are few studies comparing the efficacy and tolerability...

Full description

Bibliographic Details
Main Authors: K. Girish, K. Vikram Reddy, Lakshmi V. Pandit, H.P. Pundarikaksha, R. Vijendra, K. Vasundara, R. Manjunatha, Moulya Nagraj, R. Shruthi
Format: Article
Language:English
Published: Elsevier 2016-02-01
Series:Biomedical Journal
Subjects:
Alcohol withdrawal syndrome
Baclofen
Chlordiazepoxide
Clinical Institute Withdrawal Assessment for Alcohol-Revised Scale
Clinical Global Impression scores
Online Access:http://www.sciencedirect.com/science/article/pii/S2319417016000226

Internet

http://www.sciencedirect.com/science/article/pii/S2319417016000226

Similar Items